Deals In Depth: March 2014
In a deal worth $139 million, UCB and Sanofi are pursuing anti-inflammatory medications for GI conditions and arthritis; Sterigenics bought isotope maker Nordion for $727 million. Public offerings again drove biopharma financing, making up more than 50% of the $3.4 billion raised; device financing totaled $219 million, with most of the funding from debt and FOPO transactions.
You may also be interested in...
Sandoz has received a positive opinion from the EMA’s CHMP recommending that its high-concentration 100mg/ml adalimumab biosimilar be granted a pan-European marketing authorization. Three generics were also endorsed at the CHMP’s January meeting, including a rival to Forxiga.
Whether in the competitive world of US generics, the growing global biosimilars arena, or promising new geographical markets, Dr Reddy’s is seeking to capitalize on its strengths to remain competitive while also pushing forward with ESG goals, CEO Erez Israeli tells Generics Bulletin.
Investigational drugs from Outlook Therapeutics and Vertex/CRISPR could become first-of-their-kind products if they win marketing approval.